Core Insights - The publication of a systematic review supports the potential of off-label statin use for treating porokeratosis, highlighting the need for FDA-approved therapies [1][2][3] Company Overview - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations without FDA-approved treatments [4] - The company is developing a pipeline based on its QTORIN™ platform, with QTORIN™ pitavastatin as a lead candidate for treating disseminated superficial actinic porokeratosis [6] Industry Context - Porokeratosis is a progressive genetic skin disease with no FDA-approved therapies, characterized by expanding lesions that significantly impact patients' quality of life [3] - Recent genetic studies have identified mutations in the mevalonate pathway as key drivers of porokeratosis, leading to off-label statin use [5] - The systematic review included 24 studies with 95 patients, showing that most experienced at least partial clinical benefit from topical statin application [5]